Xtant Medical Holdings (Xtant Medical Holdings) Days Sales Outstanding

: 64.73 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Xtant Medical Holdings's average Accounts Receivable for the three months ended in Dec. 2023 was $19.94 Mil. Xtant Medical Holdings's Revenue for the three months ended in Dec. 2023 was $28.11 Mil. Hence, Xtant Medical Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 64.73.

The historical rank and industry rank for Xtant Medical Holdings's Days Sales Outstanding or its related term are showing as below:

XTNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.35 Med: 57.79 Max: 70.04
Current: 61.07

During the past 13 years, Xtant Medical Holdings's highest Days Sales Outstanding was 70.04. The lowest was 46.35. And the median was 57.79.

XTNT's Days Sales Outstanding is ranked better than
52.79% of 807 companies
in the Medical Devices & Instruments industry
Industry Median: 63.7 vs XTNT: 61.07

Xtant Medical Holdings's Days Sales Outstanding increased from Dec. 2022 (61.83) to Dec. 2023 (64.73).

Xtant Medical Holdings Days Sales Outstanding Historical Data

The historical data trend for Xtant Medical Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

56.75

58.18

46.35

56.69

63.13

Xtant Medical Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															61.83	57.86	57.83	59.99	64.73

Competitive Comparison

For the Medical Devices subindustry, Xtant Medical Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings Days Sales Outstanding Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Days Sales Outstanding falls into.

Xtant Medical Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Xtant Medical Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (10.853	+	20.731)	/	2 )	/	91.303	*	365
=	15.792					/	91.303	*	365
=	63.13

Xtant Medical Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (19.15	+	20.731)	/	2 )	/	28.108	*	365 / 4
=	19.9405					/	28.108	*	365 / 4
=	64.73

Xtant Medical Holdings (AMEX:XTNT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Xtant Medical Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750